^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    UGT2B15 expression

    i
    Other names: UGT2B15, UDP Glucuronosyltransferase Family 2 Member B15, UDP-Glucuronosyltransferase 2B15, UDP-Glucuronosyltransferase 2B8, UDPGT 2B8, UGT2B8, HLUG4, Uridine Diphosphate Glucuronosyltransferase 2 Family, Member B8, Uridine Diphosphate Glycosyltransferase 2 Family, Member B15, UDP Glucuronosyltransferase 2 Family, Polypeptide B15, UDP Glycosyltransferase 2 Family, Polypeptide B15, UDP Glucuronosyltransferase 2 Family, Member 15, UDP Glucuronosyltransferase 2 Family, Member B8, UDP-Glucuronyltran
    Entrez ID:
    7366
    Associations

    News

    Trials
    over3years
    Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action. (PubMed, Cells)
    Animal studies confirmed an inverse correlation between UGT2B15 and p53 levels. In summary, increased UGT2B15 levels in LS might confer upon patient's protection from genotoxic damage.
    Journal
    |
    TP53 (Tumor protein P53) • IGF1 (Insulin-like growth factor 1) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    TP53 mutation • TP53 wild-type • TP53 expression • UGT2B15 expression
    5years
    AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer. (PubMed, Prostate)
    This study supports the rationale to further investigate the benefits of AKR1C3 inhibition in combination with antiandrogens to prevent CRPC disease progression.
    Journal
    |
    UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    UGT2B15 expression
    over5years
    Expression of UDP Glucuronosyltransferases 2B15 and 2B17 Is Associated with Methylation Status in Prostate Cancer cells. (PubMed, Epigenetics)
    The expression of UGT2B15, UGT2B17, de novo methyltransferases, DNMT3A and DNMT3B was assessed in prostate cancer cells (LNCaP) treated with EGF; an EGFR inhibitor PD16893 and the methyltransferase inhibitor, 5-azacytidine, respectively...The results taken together suggest that hypomethylation of the UGT2B15 and UGT2B17 genes contributes to increased risk of prostate cancer and may provide a putative biomarker or epigenetic target for chemotherapeutics. Mechanistic studies are warranted to determine the role of the methylation marks in prostate cancer.
    Journal
    |
    DNMT3A (DNA methyltransferase 1) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    UGT2B15 expression
    |
    azacitidine